You are here: Industry Insights > Otezla

News List

FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level Drugs
December 27, 2021
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
Amgen looks to expand access to Otezla in the US pharmatimes
February 24, 2021
Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
BMS’ deucravacitinib beats Otezla in psoriasis study pharmatimes
February 05, 2021
Bristol Myers Squibb’s investigative drug deucravacitinib has demonstrated positive results in a Phase III trial, including showing superiority over Amgen’s Otezla (apremilast).
Amgen Announces Positive Top-Line Results from Otezla Plaque Psoriasis Study americanpharmaceuticalreview
May 08, 2020
Amgen announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with mild-to-moderate plaque psoriasis.
Amgen to acquire Otezla® for $13.4 billion in cash worldpharmanews
August 27, 2019
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire...
Amgen Acquires Rights to Celgene’s Otezla contractpharma
August 27, 2019
Expands inflammation franchise with oral, non-biologic treatment for psoriasis and psoriatic arthritis.
FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease drugs
July 22, 2019
FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease.
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion fiercepharma
October 11, 2018
When Celgene won FDA approval for its psoriasis pill Otezla in 2014, the company was entering a hugely competitive market that would become home to both established therapies and biotech newcomers from the likes ...